Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury-a retrospective analysis Article

cited authors

  • Zafar, Yousuf; Sattar, Yasar; Ullah, Waqas; Roomi, Sohaib; Mamoon-Ur-Rashid; Khan, Muhammad Shayan; Schmidt, Laura

Publication Date

  • January 2, 2020

webpage

published in

category

keywords

  • PCSK-9 inhibitors
  • Proprotein convertase subtilisin/Kexin type-9
  • alirocumab
  • clinical efficacy
  • evolocumab
  • fatty liver disease
  • hepatic steatosis
  • indications
  • side effects

start page

  • 32

end page

  • 37

volume

  • 10

issue

  • 1